1.4-dihydropyridines

US4935548A · kind A · utility

Assignee

• Glaxo SpA · IT

Inventors

• Claudio Semeraro · Bresso, IT
• Dino Micheli · Carpi, IT
• Daniele Pieraccioli · Verona, IT
• Giovanni Gaviraghi · Verona, IT
• Alan David Borthwick · London, GB

Key dates

• Filing date: Oct 21, 1988
• Grant date: Jun 19, 1990
• Expiry date: Oct 21, 2008

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P9/00
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Compounds are described of the formula ##STR1## wherein R.sub.1 represents a formyl or nitrile group or a group OCH.sub.2 A where A represents hydroxy, C.sub.1-4 alkoxy or D(CH.sub.2).sub.n NR.sub.7 R.sub.8 (where R.sub.7 and R.sub.8 independently represent hydrogen or C.sub.1-4 alkyl and n is 2 or 3); PA0 R.sub.2 and R.sub.3 independently represent a C.sub.1-6 straight or branched alkyl chain or alkoxy group; PA0 R.sub.4 represents a C.sub.1-4 alkyl group; PA0 R.sub.5 represents a straight or branched chain C.sub.1-13 alkyl group or a C.sub.5-8 cycloalkyl group which may be substituted by a C.sub.1-3 alkyl substituent; PA0 R.sub.6 represents a halogen atom or a straight or branched C.sub.1-3 alkyl group. The compounds represented by formula (I) reduce intracellular calcium ion concentration by limiting transmembranal calcium ion influx and thus may be useful for the treatment of cardiovascular disorders such as hypertension.